JPH09501165A - B型肝炎ウイルスに対する細胞毒性tリンパ球応答を誘発するためのペプチド - Google Patents
B型肝炎ウイルスに対する細胞毒性tリンパ球応答を誘発するためのペプチドInfo
- Publication number
- JPH09501165A JPH09501165A JP7506053A JP50605395A JPH09501165A JP H09501165 A JPH09501165 A JP H09501165A JP 7506053 A JP7506053 A JP 7506053A JP 50605395 A JP50605395 A JP 50605395A JP H09501165 A JPH09501165 A JP H09501165A
- Authority
- JP
- Japan
- Prior art keywords
- leu
- hbpol
- seq
- tyr
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 350
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title claims abstract description 152
- 241000700721 Hepatitis B virus Species 0.000 title claims abstract description 5
- 230000004044 response Effects 0.000 title claims description 67
- 230000001939 inductive effect Effects 0.000 title claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 155
- 208000015181 infectious disease Diseases 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 50
- 230000004936 stimulating effect Effects 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 106
- 150000001413 amino acids Chemical class 0.000 claims description 37
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 23
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 23
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 13
- 239000002502 liposome Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 9
- 150000002632 lipids Chemical class 0.000 claims description 7
- 206010059193 Acute hepatitis B Diseases 0.000 claims description 4
- 208000037628 acute hepatitis B virus infection Diseases 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims 2
- 208000036141 Viral hepatitis carrier Diseases 0.000 claims 1
- 208000016350 chronic hepatitis B virus infection Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003136 immunomodifying effect Effects 0.000 claims 1
- 108091007433 antigens Proteins 0.000 abstract description 48
- 102000036639 antigens Human genes 0.000 abstract description 48
- 239000000427 antigen Substances 0.000 abstract description 46
- 108700024845 Hepatitis B virus P Proteins 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 10
- 230000028993 immune response Effects 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 description 46
- 235000001014 amino acid Nutrition 0.000 description 35
- 229960005486 vaccine Drugs 0.000 description 23
- 230000001684 chronic effect Effects 0.000 description 20
- 230000027455 binding Effects 0.000 description 19
- 230000001154 acute effect Effects 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 210000001744 T-lymphocyte Anatomy 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 14
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 13
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 13
- 230000001472 cytotoxic effect Effects 0.000 description 13
- 230000001404 mediated effect Effects 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 238000003556 assay Methods 0.000 description 10
- 208000006454 hepatitis Diseases 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 108700028369 Alleles Proteins 0.000 description 9
- 231100000433 cytotoxic Toxicity 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 241000700618 Vaccinia virus Species 0.000 description 7
- 230000000735 allogeneic effect Effects 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108091054437 MHC class I family Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 206010008909 Chronic Hepatitis Diseases 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 4
- 102000043129 MHC class I family Human genes 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 206010046865 Vaccinia virus infection Diseases 0.000 description 4
- -1 amino acids Acids Chemical class 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- 229920000140 heteropolymer Polymers 0.000 description 4
- 229920001519 homopolymer Polymers 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000007089 vaccinia Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 150000008574 D-amino acids Chemical group 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 208000037581 Persistent Infection Diseases 0.000 description 3
- 231100000354 acute hepatitis Toxicity 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000009435 amidation Effects 0.000 description 3
- 238000007112 amidation reaction Methods 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000001461 cytolytic effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 2
- 101710112752 Cytotoxin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 2
- 108010086377 HLA-A3 Antigen Proteins 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- MEZJQXVOMGUAMP-UHFFFAOYSA-N 1-(2-methylnaphthalen-1-yl)pyrrole-2,5-dione Chemical compound CC1=CC=C2C=CC=CC2=C1N1C(=O)C=CC1=O MEZJQXVOMGUAMP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- WOJKKJKETHYEAC-UHFFFAOYSA-N 6-Maleimidocaproic acid Chemical compound OC(=O)CCCCCN1C(=O)C=CC1=O WOJKKJKETHYEAC-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- RDIKFPRVLJLMER-BQBZGAKWSA-N Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)N RDIKFPRVLJLMER-BQBZGAKWSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- REIAEKYJJUNGEO-UHFFFAOYSA-J C(C(O)C)(=O)[O-].[Th+4].C(C(O)C)(=O)[O-].C(C(O)C)(=O)[O-].C(C(O)C)(=O)[O-] Chemical compound C(C(O)C)(=O)[O-].[Th+4].C(C(O)C)(=O)[O-].C(C(O)C)(=O)[O-].C(C(O)C)(=O)[O-] REIAEKYJJUNGEO-UHFFFAOYSA-J 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930182847 D-glutamic acid Natural products 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102100023933 Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- WRPDZHJNLYNFFT-GEVIPFJHSA-N His-Thr Chemical compound C[C@@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N)O WRPDZHJNLYNFFT-GEVIPFJHSA-N 0.000 description 1
- 101000986079 Homo sapiens HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 1
- 102000017095 Leukocyte Common Antigens Human genes 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- MYTOTTSMVMWVJN-STQMWFEESA-N Lys-Tyr Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 MYTOTTSMVMWVJN-STQMWFEESA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010046117 N-palmitoyl-5,6-dipalmitoyl-S-glycerylcysteinyl-seryl-serine Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- NFDYGNFETJVMSE-BQBZGAKWSA-N Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CO NFDYGNFETJVMSE-BQBZGAKWSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OATNQHYJXLHTEW-UHFFFAOYSA-N benzene-1,4-disulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(S(O)(=O)=O)C=C1 OATNQHYJXLHTEW-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-N bromoacetic acid Chemical compound OC(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-N 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000013546 insoluble monolayer Substances 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108020002447 serine esterase Proteins 0.000 description 1
- 102000005428 serine esterase Human genes 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- XVQKZSLOGHBCET-INVHGPFASA-N tripalmitoyl-S-glyceryl-cysteinyl-seryl-serine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O)CSCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC XVQKZSLOGHBCET-INVHGPFASA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.8〜13個のアミノ酸を含んで成るCTL誘発ペプチドであって、前記アミノ 酸の少なくとも大多数が下記配列: HBpol 4-13〔配列番号12〕 Ser-Tyr-Gln-His-Phe-Arg-Lys-Leu-Leu-Leu; HBpol 108-116 〔配列番号13〕 Arg-Leu-Lys-Leu-Ile-Met-Pro-Ala-Arg; HBpol 139-147 〔配列番号14〕 Val-Val-Asn-His-Tyr-Phe-Gln-Thr-Arg HBpol 151-160 〔配列番号15〕 His-Thr-Leu-Trp-Lys-Ala-Gly-Ile-Leu-Tyr HBpol 152-161 〔配列番号16〕 Thr-Leu-Trp-Lys-Ala-Gly-Ile-Leu-Tyr-Lys HBpol 455-463 〔配列番号2〕 Gly-Leu-Ser-Arg-Tyr-Val-Ala-Arg-Leu; HBpol 505-514 〔配列番号17〕 Leu-Tyr-Ser-His-Pro-Ile-Ile-Leu-Gly-Phe; HBpol 551-559 〔配列番号18〕 Tyr-Met-Asp-Asp-Val-Val-Leu-Gly-Ala; HBpol 575-583 〔配列番号19〕 Phe-Leu-Leu-Ser-Leu-Gly-Ile-His-Leu; HBpol 655-663 〔配列番号20〕 Ala-Leu-Met-Pro-Leu-Tyr-Ala-Cys-Ile; HBpol 748-757 〔配列番号21〕 Gly-Thr-Asp-Asn-Ser-Val-Val-Leu-Ser-Arg; HBpol 758-766 〔配列番号22〕 Lys-Tyr-Thr-Ser-Phe-Pro-Trp-Leu-Leu; HBpol 773-782 〔配列番号3〕 Ile-Leu-Arg-Gly-Thr-Ser-Phe-Val-Tyr-Val;又は HBpol 816-824 〔配列番号5〕 Phe-Leu-Leu-Ser-Leu-Gly-Ile-His-Leu を有するHBpolの対応する部分に相同であるCTL誘発ペプチド。 2.9〜11個のアミノ酸を含んで成る請求の範囲第1項記載のCTL誘発ペプチ ド。 3.下記配列: HBpol 4-13〔配列番号12〕 Ser-Tyr-Gln-His-Phe-Arg-Lys-Leu-Leu-Leu; HBpol 108-116 〔配列番号13〕 Arg-Leu-Lys-Leu-Ile-Met-Pro-Ala-Arg; HBpol 139-147 〔配列番号14〕 Val-Val-Asn-His-Tyr-Phe-Gln-Thr-Arg HBpol 151-160 〔配列番号15〕 His-Thr-Leu-Trp-Lys-Ala-Gly-Ile-Leu-Tyr HBpol 152-161 〔配列番号16〕 Thr-Leu-Trp-Lys-Ala-Gly-Ile-Leu-Tyr-Lys HBpol 455-463 〔配列番号2〕 Gly-Leu-Ser-Arg-Tyr-Val-Ala-Arg-Leu; HBpol 505-514 〔配列番号17〕 Leu-Tyr-Ser-His-Pro-Ile-Ile-Leu-Gly-Phe; HBpol 551-559 〔配列番号18〕 Tyr-Met-Asp-Asp-Val-Val-Leu-Gly-Ala; HBpol 575-583 〔配列番号19〕 Phe-Leu-Leu-Ser-Leu-Gly-Ile-His-Leu; HBpol 655-663 〔配列番号20〕 Ala-Leu-Met-Pro-Leu-Tyr-Ala-Cys-Ile; HBpol 748-757 〔配列番号21〕 Gly-Thr-Asp-Asn-Ser-Val-Val-Leu-Ser-Arg; HBpol 758-766 〔配列番号22〕 Lys-Tyr-Thr-Ser-Phe-Pro-Trp-Leu-Leu; HBpol 773-782 〔配列番号3〕 Ile-Leu-Arg-Gly-Thr-Ser-Phe-Val-Tyr-Val;又は HBpol 816-824 〔配列番号5〕 Phe-Leu-Leu-Ser-Leu-Gly-Ile-His-Leu を含んで成る請求の範囲第1項記載のCTL誘発ペプチド。 4.リポソームを含んで成る医薬的に許容できるキャリヤーに懸濁される請求 の範囲第1項記載のCTL誘発ペプチド。 5.前記ペプチドがまた、Tヘルパーエピトープを含む請求の範囲第1項記載 のCTL誘発ペプチド。 6.免疫変性脂質キャリヤーに接合される請求の範囲第1項記載のCTL誘発ペ プチド。 7.B型肝炎ウイルスに対する細胞毒性Tリンパ球応答を刺激するための方法 であって、CTLエピトープを含み、そして8〜13個のアミノ酸を含んで成るペプ チドに宿主の細胞毒性Tリンパ球を暴露することを含んで成り、ここで前記アミ ノ酸の少なくとも大多数が下記配列: HBpol 4-13〔配列番号12〕 Ser-Tyr-Gln-His-Phe-Arg-Lys-Leu-Leu-Leu; HBpol 108-116 〔配列番号13〕 Arg-Leu-Lys-Leu-Ile-Met-Pro-Ala-Arg; HBpol 139-147 〔配列番号14〕 Val-Val-Asn-His-Tyr-Phe-Gln-Thr-Arg HBpol 151-160 〔配列番号15〕 His-Thr-Leu-Trp-Lys-Ala-Gly-Ile-Leu-Tyr HBpol 152-161 〔配列番号16〕 Thr-Leu-Trp-Lys-Ala-Gly-Ile-Leu-Tyr-Lys HBpol 455-463 〔配列番号2〕 Gly-Leu-Ser-Arg-Tyr-Val-Ala-Arg-Leu; HBpol 505-514 〔配列番号17〕 Leu-Tyr-Ser-His-Pro-Ile-Ile-Leu-Gly-Phe; HBpol 551-559 〔配列番号18〕 Tyr-Met-Asp-Asp-Val-Val-Leu-Gly-Ala; HBpol 575-583 〔配列番号19〕 Phe-Leu-Leu-Ser-Leu-Gly-Ile-His-Leu; HBpol 655-663 〔配列番号20〕 Ala-Leu-Met-Pro-Leu-Tyr-Ala-Cys-Ile; HBpol 748-757 〔配列番号21〕 Gly-Thr-Asp-Asn-Ser-Val-Val-Leu-Ser-Arg; HBpol 758-766 〔配列番号22〕 Lys-Tyr-Thr-Ser-Phe-Pro-Trp-Leu-Leu; HBpol 773-782 〔配列番号3〕 Ile-Leu-Arg-Gly-Thr-Ser-Phe-Val-Tyr-Val;又は HBpol 816-824 〔配列番号5〕 Phe-Leu-Leu-Ser-Leu-Gly-Ile-His-Leu を有するHBpolの対応する部分に相同であることを特徴とする方法。 8.前記CTL誘発ペプチドが、下記配列: HBpol 4-13〔配列番号12〕 Ser-Tyr-Gln-His-Phe-Arg-Lys-Leu-Leu-Leu; HBpol 108-116 〔配列番号13〕 Arg-Leu-Lys-Leu-Ile-Met-Pro-Ala-Arg; HBpol 139-147 〔配列番号14〕 Val-Val-Asn-His-Tyr-Phe-Gln-Thr-Arg HBpol 151-160 〔配列番号15〕 His-Thr-Leu-Trp-Lys-Ala-Gly-Ile-Leu-Tyr HBpol 152-161 〔配列番号16〕 Thr-Leu-Trp-Lys-Ala-Gly-Ile-Leu-Tyr-Lys HBpol 455-463 〔配列番号2〕 Gly-Leu-Ser-Arg-Tyr-Val-Ala-Arg-Leu; HBpol 505-514 〔配列番号17〕 Leu-Tyr-Ser-His-Pro-Ile-Ile-Leu-Gly-Phe; HBpol 551-559 〔配列番号18〕 Tyr-Met-Asp-Asp-Val-Val-Leu-Gly-Ala; HBpol 575-583 〔配列番号19〕 Phe-Leu-Leu-Ser-Leu-Gly-Ile-His-Leu; HBpol 655-663 〔配列番号20〕 Ala-Leu-Met-Pro-Leu-Tyr-Ala-Cys-Ile; HBpol 748-757 〔配列番号21〕 Gly-Thr-Asp-Asn-Ser-Val-Val-Leu-Ser-Arg; HBpol 758-766 〔配列番号22〕 Lys-Tyr-Thr-Ser-Phe-Pro-Trp-Leu-Leu; HBpol 773-782 〔配列番号3〕 Ile-Leu-Arg-Gly-Thr-Ser-Phe-Val-Tyr-Val;又は HBpol 816-824 〔配列番号5〕 Phe-Leu-Leu-Ser-Leu-Gly-Ile-His-Leu である請求の範囲第7項記載の方法。 9.前記CTL誘発ペプチドに暴露される宿主細胞がHLA-A2である請求の範囲第 8項記載の方法。 10.前記細胞毒性T細胞が、前記CTL誘発ペプチドに暴露される前、宿主から 除去される請求の範囲第8項記載の方法。 11.前記刺激されたCTLを前記宿主に戻す段階をさらに含んで成る請求の範囲 第10項記載の方法。 12.前記宿主が慢性B型肝炎感染を有し、又はB型肝炎キャリヤーである請求 の範囲第8項記載の方法。 13.前記宿主が急性B型肝炎感染を有する請求の範囲第8項記載の方法。 14.前記CTL誘発ペプチドが宿主細胞に予防的に投与される請求の範囲第8項 記載の方法。 15.前記CTL誘発ペプチドが、HBVに対するTヘルパー応答を誘発する第2ペプ チドを有する宿主に投与される請求の範囲第8項記載の方法。 16.前記CTL誘発ペプチド及びTヘルパー誘発ペプチドが連結されている請求 の範囲第15項記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10087093A | 1993-08-02 | 1993-08-02 | |
US08/100,870 | 1993-08-02 | ||
PCT/US1994/008685 WO1995003777A1 (en) | 1993-08-02 | 1994-08-01 | Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004287144A Division JP2005170926A (ja) | 1993-08-02 | 2004-09-30 | B型肝炎ウイルスに対する細胞毒性tリンパ球応答を誘発するためのペプチド |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09501165A true JPH09501165A (ja) | 1997-02-04 |
JP3650110B2 JP3650110B2 (ja) | 2005-05-18 |
Family
ID=22281958
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50605395A Expired - Fee Related JP3650110B2 (ja) | 1993-08-02 | 1994-08-01 | B型肝炎ウイルスに対する細胞毒性tリンパ球応答を誘発するためのペプチド |
JP2004287144A Pending JP2005170926A (ja) | 1993-08-02 | 2004-09-30 | B型肝炎ウイルスに対する細胞毒性tリンパ球応答を誘発するためのペプチド |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004287144A Pending JP2005170926A (ja) | 1993-08-02 | 2004-09-30 | B型肝炎ウイルスに対する細胞毒性tリンパ球応答を誘発するためのペプチド |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0726758B1 (ja) |
JP (2) | JP3650110B2 (ja) |
AT (1) | ATE227118T1 (ja) |
AU (1) | AU702367B2 (ja) |
CA (1) | CA2168583C (ja) |
DE (1) | DE69431665T2 (ja) |
DK (1) | DK0726758T3 (ja) |
ES (1) | ES2187530T3 (ja) |
NZ (1) | NZ271531A (ja) |
PT (1) | PT726758E (ja) |
WO (1) | WO1995003777A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003535024A (ja) * | 1999-06-29 | 2003-11-25 | エピミューン インコーポレイテッド | Hla結合ペプチドおよびそれらの使用 |
JP2017518051A (ja) * | 2014-06-02 | 2017-07-06 | アイエスエー ファーマシューティカルズ ビー.ヴイ.ISA Pharmaceuticals B.V. | B型肝炎ウイルス感染に対する治療ワクチン接種のための合成長鎖ペプチド(slp) |
JP2021522807A (ja) * | 2018-05-09 | 2021-09-02 | ソウル大学校産学協力団Seoul National University R&Db Foundation | B型肝炎ウイルス由来ポリペプチド及びその抗ウイルス用途 |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6607727B1 (en) | 1991-08-26 | 2003-08-19 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus |
US7611713B2 (en) | 1993-03-05 | 2009-11-03 | Pharmexa Inc. | Inducing cellular immune responses to hepatitis B virus using peptide compositions |
US6689363B1 (en) | 1992-01-29 | 2004-02-10 | Epimmune Inc. | Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions |
US6235288B1 (en) | 1992-08-26 | 2001-05-22 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
US5858689A (en) * | 1993-07-22 | 1999-01-12 | Ludwig Institute For Cancer Research | Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof |
ES2367640T3 (es) * | 1996-03-11 | 2011-11-07 | Epimmune Inc. | Péptidos con afinidad de unión aumentada para al menos tres moléculas de tipo hla-a3. |
WO1999036434A1 (en) * | 1998-01-19 | 1999-07-22 | Mogam Biotechnology Research Institute | Liposomes comprising peptide antigens derived from x protein of hepatitis b virus |
EP1619207A3 (en) * | 2000-09-01 | 2006-02-08 | Epimmune Inc. | HLA-A2.1 binding peptides derived from HCV and their uses |
US20100216722A1 (en) * | 2007-09-11 | 2010-08-26 | Dorian Bevec | Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent |
US9249187B2 (en) | 2009-01-28 | 2016-02-02 | Epimmune Inc. | Pan-DR binding polypeptides and uses thereof |
TWI575070B (zh) | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Hbv聚合酶突變體 |
GB201223386D0 (en) | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
JP7250520B2 (ja) | 2016-04-13 | 2023-04-03 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 組換えアルテリウイルスレプリコン系およびその使用 |
CN117018170A (zh) | 2016-06-20 | 2023-11-10 | Isa制药有限公司 | 肽疫苗制剂 |
WO2018075235A1 (en) | 2016-10-17 | 2018-04-26 | Synthetic Genomics, Inc. | Recombinant virus replicon systems and uses thereof |
US11845939B2 (en) | 2016-12-05 | 2023-12-19 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
EA202091516A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) |
MA51311A (fr) * | 2017-12-19 | 2020-10-28 | Janssen Sciences Ireland Unlimited Co | Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées |
EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
US11083786B2 (en) | 2018-01-19 | 2021-08-10 | Janssen Pharmaceuticals, Inc. | Induce and enhance immune responses using recombinant replicon systems |
CA3226957A1 (en) * | 2021-07-30 | 2023-02-02 | Tevogen Bio Inc. | Methods for developing cd3+cd8+ cells against multiple viral epitopes for treatment of viral infections including variants evolving to escape previous immunity |
CN114478711A (zh) * | 2022-01-05 | 2022-05-13 | 成都朗谷生物科技股份有限公司 | 一种针对乙型肝炎病毒的抗原肽及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE320444T1 (de) * | 1991-08-26 | 2006-04-15 | Scripps Research Inst | Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren |
IL106610A0 (en) * | 1992-08-07 | 1993-12-08 | Cytel Corp | Hla binding peptides and their uses |
ATE466869T1 (de) * | 1993-03-05 | 2010-05-15 | Epimmune Inc | Verfahren zur herstellung von immunogenen hla- a2.1-bindenden peptiden |
-
1994
- 1994-08-01 DE DE69431665T patent/DE69431665T2/de not_active Expired - Lifetime
- 1994-08-01 EP EP94925160A patent/EP0726758B1/en not_active Expired - Lifetime
- 1994-08-01 JP JP50605395A patent/JP3650110B2/ja not_active Expired - Fee Related
- 1994-08-01 AU AU75184/94A patent/AU702367B2/en not_active Ceased
- 1994-08-01 AT AT94925160T patent/ATE227118T1/de active
- 1994-08-01 WO PCT/US1994/008685 patent/WO1995003777A1/en active IP Right Grant
- 1994-08-01 ES ES94925160T patent/ES2187530T3/es not_active Expired - Lifetime
- 1994-08-01 NZ NZ271531A patent/NZ271531A/en not_active IP Right Cessation
- 1994-08-01 CA CA002168583A patent/CA2168583C/en not_active Expired - Fee Related
- 1994-08-01 DK DK94925160T patent/DK0726758T3/da active
- 1994-08-01 PT PT94925160T patent/PT726758E/pt unknown
-
2004
- 2004-09-30 JP JP2004287144A patent/JP2005170926A/ja active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003535024A (ja) * | 1999-06-29 | 2003-11-25 | エピミューン インコーポレイテッド | Hla結合ペプチドおよびそれらの使用 |
JP2017518051A (ja) * | 2014-06-02 | 2017-07-06 | アイエスエー ファーマシューティカルズ ビー.ヴイ.ISA Pharmaceuticals B.V. | B型肝炎ウイルス感染に対する治療ワクチン接種のための合成長鎖ペプチド(slp) |
JP2021522807A (ja) * | 2018-05-09 | 2021-09-02 | ソウル大学校産学協力団Seoul National University R&Db Foundation | B型肝炎ウイルス由来ポリペプチド及びその抗ウイルス用途 |
Also Published As
Publication number | Publication date |
---|---|
DE69431665T2 (de) | 2003-08-21 |
EP0726758A4 (en) | 1997-01-29 |
CA2168583A1 (en) | 1995-02-09 |
JP3650110B2 (ja) | 2005-05-18 |
PT726758E (pt) | 2003-03-31 |
ATE227118T1 (de) | 2002-11-15 |
WO1995003777A1 (en) | 1995-02-09 |
JP2005170926A (ja) | 2005-06-30 |
DE69431665D1 (de) | 2002-12-12 |
AU702367B2 (en) | 1999-02-18 |
ES2187530T3 (es) | 2003-06-16 |
DK0726758T3 (da) | 2003-03-03 |
EP0726758B1 (en) | 2002-11-06 |
AU7518494A (en) | 1995-02-28 |
NZ271531A (en) | 1998-02-26 |
CA2168583C (en) | 2007-10-02 |
EP0726758A1 (en) | 1996-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3650110B2 (ja) | B型肝炎ウイルスに対する細胞毒性tリンパ球応答を誘発するためのペプチド | |
US5780036A (en) | Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus | |
US7744898B2 (en) | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus | |
US7252829B1 (en) | HLA binding peptides and their uses | |
JP4210734B2 (ja) | Hla結合ペプチド及びその使用 | |
US7368118B2 (en) | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus | |
JP3657603B2 (ja) | B型肝炎のウイルスに対する細胞障害性tリンパ球の応答を誘発するペプチド | |
JP3694300B2 (ja) | B型肝炎ウイルスに対する細胞障害性tリンパ球の応答を誘発するペプチド | |
US20020098197A1 (en) | Hla binding peptides and their uses | |
JP2010090167A (ja) | Hla結合ペプチドおよびそれらの用途 | |
JP2003524016A (ja) | Hla結合ペプチドおよびそれらの用途 | |
JP2004517609A (ja) | Hla−a2.1結合ペプチドおよびそれらの用途 | |
CA2156416C (en) | Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus | |
JP2010001303A (ja) | Hla結合ペプチド及びその使用 | |
AU4754899A (en) | HLA Binding peptides and their uses | |
CA2594184A1 (en) | Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus | |
KR20030036139A (ko) | Hla 결합 펩티드 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040128 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040330 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040629 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040809 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040930 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050118 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050217 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080225 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090225 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100225 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100225 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110225 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120225 Year of fee payment: 7 |
|
LAPS | Cancellation because of no payment of annual fees |